20
Participants
Start Date
January 3, 2023
Primary Completion Date
August 5, 2024
Study Completion Date
August 5, 2024
Velaglucerase Alfa
VPRIV intravenous infusion every other week for 60 minutes.
Chinese PLA General Hospital, Beijing
Beijing Children's Hospital, Capital Medical University, Beijing
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing
Nanjing Children's Hospital, Nanjing
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
Guangzhou Women and Children's Medical Center, Guangzhou
Lanzhou University Second Hospital, Lanzhou
The Second Hospital of Hebei Medical University, Shijiazhuang
Lead Sponsor
Takeda
INDUSTRY